• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
98% Bifida Ferment Lysate
rhSOD (cosmetic grade)
Recombinant humanized collagen
Recombinant Humanized Small-molecule Collagen
Recombinant Humanized Small-molecule Collagen Solution
rhSOD

UK to invest up to 93 million pounds in new coronavirus vaccine centre

expresspharmaMay 19, 2020

Tag: UK , coronavirus vaccine , VMIC

The British government will invest up to 93 million pounds ($112 million) to accelerate construction of a new vaccines centre, the Department for Business, Energy and Industrial Strategy said.

The funding will ensure the new centre opens in Summer 2021, a year ahead of schedule, the department said.

The Vaccines Manufacturing and Innovation Centre (VMIC), which is currently under construction, is a key component of the government’s programme to ensure that once a coronavirus vaccine is available it can be rolled out quickly in mass quantities, the department said.


Previous:New research into stem cell mutations could improve regenerative medicine

Next:Sorrento’s antibody completely blocks Covid-19 in-vitro

Related News

Pharus Diagnostics LLC Announces Validation of a Laboratory-Developed Test for Early Pancreatic Cancer Detection

PRNewswireDecember 19, 2024

Pharus Diagnostics LLC. (PharusDx), announced a significant step forward in the fight against pancreatic cancer. The company is announcing availability of its OncoSweep™ Pancreas Spotlight

Prenetics' IM8 Announces Collaboration with Mayo Clinic to Develop New Line of Premium Supplements

PRNewswireDecember 19, 2024

PeproMene Bio, Inc. and the Institute for Follicular Lymphoma Innovation Announce $11M Investment to Advance PMB-CT01 (BAFF-R CAR T cell therapy) for Relapsed/Refractory Follicular Lymphoma

PRNewswireDecember 19, 2024

UK to invest up to 93 million pounds in new coronavirus vaccine centre | Pharmasources.com

Innovent Receives Approval of DOVBLERON® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration

PRNewswireDecember 20, 2024

Innovent Biologics announced that China's National Medical Products Administration (NMPA) has approved a New Drug Application (NDA) of DOVBLERON ® .

You may like
More>>

Montelukast Intermediate

Montelukast Intermediate
ZAFIRLUKAST

ZAFIRLUKAST
70% 70 Food Grade Sapindus Mukurossi Peel Sapphora Seed Mukorossi Garet Soapnut Extract Powder

70% 70 Food Grade Sapindus Mukurossi Peel Sapphora Seed Mukorossi Garet Soapnut Extract Powder
Antileukinate

Antileukinate
Recombinant Human Interleukin-11

Recombinant Human Interleukin-11
DACHAIHUKELI

DACHAIHUKELI
Adsuki Bean extract powder

Adsuki Bean extract powder
Montelukast Sodium Tablets 4mg, 5mg

Montelukast Sodium Tablets 4mg, 5mg
Montelukast

Montelukast
Montelukast Sodium Chewable Tablets 10mg

Montelukast Sodium Chewable Tablets 10mg

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service